期刊文献+

Stroma-targeting strategies in pancreatic cancer:Past lessons,challenges and prospects 被引量:1

下载PDF
导出
摘要 Pancreatic ductal adenocarcinoma(PDAC)is projected to emerge as the second leading cause of cancer-related death after 2030.Extreme treatment resistance is perhaps the most significant factor that underlies the poor prognosis of PDAC.To date,combination chemotherapy remains the mainstay of treatment for most PDAC patients.Compared to other cancer types,treatment response of PDAC tumors to similar chemotherapy regimens is clearly much lower and shorterlived.Aside from typically harboring genetic alterations that to date remain undruggable and are drivers of treatment resistance,PDAC tumors are uniquely characterized by a densely fibrotic stroma that has well-established roles in promoting cancer progression and treatment resistance.However,emerging evidence also suggests that indiscriminate targeting and near complete depletion of stroma may promote PDAC aggressiveness and lead to detrimental outcomes.These conflicting results undoubtedly warrant the need for a more in-depth understanding of the heterogeneity of tumor stroma in order to develop modulatory strategies in favor of tumor suppression.The advent of novel techniques including single cell RNA sequencing and multiplex immunohistochemistry have further illuminated the complex heterogeneity of tumor cells,stromal fibroblasts,and immune cells.This new knowledge is instrumental for development of more refined therapeutic strategies that can ultimately defeat this disease.Here,we provide a concise review on lessons learned from past stromatargeting strategies,new challenges revealed from recent preclinical and clinical studies,as well as new prospects in the treatment of PDAC.
机构地区 Division of Oncology
出处 《World Journal of Gastroenterology》 SCIE CAS 2021年第18期2105-2121,共17页 世界胃肠病学杂志(英文版)
基金 National Institutes of Health/National Cancer Institute,No.5R37CA219697-01(to Lim KH) American Cancer Society,No.RSG-17-203-01-TBG(to Lim KH) and Alvin J.Siteman Cancer Center Siteman Investment Program(from Barnard Trust and The Foundation for Barnes-Jewish Hospital)(to Lim KH) and Emerson Collective Grant(to Grierson PM).
  • 相关文献

参考文献1

二级参考文献4

共引文献3

同被引文献2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部